Positron emission tomography (PET) study with (11C) flumazenil to determine central GABAA receptor occupancy of AZD6280 - PET
Study identifier:D0850C00011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open label positron emission tomography (PET) study with (11C)flumazenil to determine central GABAA receptor occupancy of AZD6280 after oral administration to healthy volunteers
Medical condition
Anxiety
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6280, (11C) flumazenil
Sex
Male
Actual Enrollment
8
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Feb 2008
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008
Study design
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2008 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD6280 Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects. Drug: (11C) flumazenil Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280) |
Contacts
Investigators
Principal Investigator
Bo Fransson
AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden
